Clinical trials: Anthracycline-induced Cardiac Toxicity
Wilms Tumor, Neuroblastoma
Pharmacokinetic Study of Doxorubicin in Children With Cancer
Analyze pharmacokinetics of doxorubicin in children with cancer. Furthermore investigate the predictive role of troponin and natriuretic peptides for anthracycline-induced cardiotoxicity .
- Conditions
- Wilms Tumor, Neuroblastoma, Soft Tissue Sarcoma, Acute Lymphoblastic Leukemia
- Trial name
- Doxo (NCT01095926)
- Testing
- doxorubicin
- Where
- 23 sites in France, Germany and 2 more
- Volunteers
- 101 people
- Sponsor
- University Hospital Muenster
Childhood Cancer Survivors, Cardiotoxicity
Impact of Exercise Intensity on Cardiac Health in Young Adult Survivors of Childhood Cancer: The PULSE Trial
This trial aims to evaluate the impact of exercise intensity on cardiac health in young adult survivors of childhood cancer previously treated with anthracyclines.
- Conditions
- Childhood Cancer Survivors, Cardiotoxicity, Cardiovascular Diseases, Anthracycline-induced Cardiotoxicity
- Trial name
- PULSE (NCT07442578)
- Testing
- HIIT Exercise Program, MICT Exercise Program
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Cancer, Doxorubicin Induced Cardiomyopathy
Telmisartan for Prevention of Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients
This study aims to evaluate the efficacy and safety of telmisartan as a cardioprotective agent in patients receiving doxorubicin-based chemotherapy, with the goal of reducing treatment-associated cardiotoxicity, optimizing…
- Trial name
- NCT07370506
- Testing
- Telmisartan, Doxorubicin (DOX)
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Tanta University
Cancer
Prevention of Anthracycline-induced Cardiotoxicity
Anthracycline based anti-tumoral therapies are know to develop cardiac damage that could also lead to heart failure. Monocentric studies proved that a treatment with ACE inhibitors (ACEi) and betablockers (BB) during the first…
- Trial name
- ICOS-ONE (NCT01968200)
- Testing
- Enalapril
- Where
- Italy
- Volunteers
- 268 people
- Sponsor
- European Institute of Oncology
Anthracycline-induced Cardiotoxicity, Lymphoma
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity
This project aims to determine the benefits of the dual SGLT1/2 inhibition as prophylactic treatment to prevent anthracycline-related cardiotoxicity.
- Conditions
- Anthracycline-induced Cardiotoxicity, Lymphoma, Chemotherapy, Cardiotoxicity
- Trial name
- SPARTACUS (NCT07572175)
- Testing
- Sotagliflozin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer, Metastatic Breast Cancer
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Cancer Therapy-Related Cardiac Dysfunction, Cardiotoxicity
- Trial name
- NARNIA (NCT05732051)
- Testing
- Nicotinamide Riboside
- Where
- Norway
- Volunteers
- 60 people
- Sponsor
- University Hospital, Akershus
Childhood Cancer
Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity
Early microRNAs (miRs) and Cardiac Magnetic Resonance (CMR)-derived strain analysis and detection of genes contributing to Anthracycline-Induced Cardiotoxicity (AIC) sensitivity and resistance will identify pediatric cancer…
- Trial name
- NCT04036045
- Testing
- Cardiac MRI, Echocardiogram, Blood Draw
- Where
- United States
- Sponsor
- Connecticut Children's Medical Center
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Enalapril in Treating Heart Damage Patients Who Received Anthracycline Chemotherapy for Childhood Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as enalapril, may protect normal cells from the toxic effects of chemotherapy.
- Trial name
- NCT00003070
- Testing
- enalapril maleate, quality-of-life assessment
- Where
- 61 sites in United States, Canada and 1 more
- Volunteers
- 13 people
- Sponsor
- Children's Oncology Group
Cardiotoxicity, Neoplasms
Effect of Spironolactone in the Prevention of Anthracycline-induced Cardiotoxicity (SPIROTOX)
The goal of this clinical trial is to evaluate the effect of spironolactone in the primary prevention of cardiotoxicity in cancer patients who are undergoing chemotherapy with anthracycline within 12 months.
- Conditions
- Cardiotoxicity, Neoplasms, Chemotherapy Effect, Heart Failure
- Trial name
- SPIROTOX (NCT06005259)
- Testing
- Spironolactone
- Where
- Brazil
- Volunteers
- 264 people
- Sponsor
- University of Sao Paulo
Acute Myeloid Leukemia, Adult, Cardiotoxicity
Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML
Acute myeloid leukemia (AML) is a clonal neoplastic disease of the hematopoietic tissue associated with a mutation in the precursor cell of hematopoiesis, which results in a differentiation block and uncontrolled proliferation of…
- Conditions
- Acute Myeloid Leukemia, Adult, Cardiotoxicity, Endothelial Dysfunction
- Trial name
- NCT05703126
- Testing
- History taking, Anthropometry, Complete blood count
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- Samara State Medical University
Cardiotoxicity, Cardiac Rehabilitation
Exercise-based Cardiac Rehabilitation for the Prevention of Breast Cancer Chemotherapy-induced Cardiotoxicity
This project aims to determine whether a comprehensive cardiac rehabilitation program including supervised exercise training is able to prevent cardiotoxicity during treatment with anthracyclines and / or anti-HER-2 antibodies in…
- Trial name
- ONCORE (NCT03964142)
- Testing
- Cardiac rehabilitation
- Where
- Spain
- Volunteers
- 122 people
- Sponsor
- Hospital Clinico Universitario de Santiago
Cancer
Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy
Neoplasia is the main cause of general death in the Brazilian population. In 2016, they were responsible for approximately 211,343 (16%) deaths, followed by cardiovascular diseases (12.6%).
- Trial name
- CardioTox (NCT04939883)
- Testing
- Carvedilol
- Where
- Brazil
- Volunteers
- 1,018 people
- Sponsor
- Hospital Sirio-Libanes
Lymphoma, Large B-Cell
Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell
All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec.
- Conditions
- Lymphoma, Large B-Cell, Diffuse Large B-Cell
- Trial name
- NCT02916316
- Testing
- R-CHOP with doxorubicin
- Where
- 18 sites in Italy
- Volunteers
- 127 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Cancer, Cardiotoxicity
Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy
Over 50% of the more than 270,000 childhood cancer survivors in the U.S. have been treated with anthracyclines and thus are at risk of developing cardiotoxicity.
- Trial name
- NCT04036032
- Testing
- Exercise program
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Connecticut Children's Medical Center
Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer
ANTthracycline-induced Inflammation and OXidative Stress: 10-year Follow-up
The goal of this observational study is to learn about the long-term effects of anthracycline chemotherapy on inflammation, oxidative stress, and heart function in adult women with breast cancer.
- Conditions
- Cardiotoxicity, Anthracycline Related Cardiotoxicity in Breast Cancer, Breast Cancer
- Trial name
- ANTIOX-10 (NCT07680855)
- Volunteers
- 17 people
- Sponsor
- University of Chile
Anthracycline-induced Cardiotoxicity
Preventing Cardiac Sequelae in Pediatric Cancer Survivors
Cancer therapy can place childhood cancer survivors at increased risk for heart disease which can lead to significant illness or early death.
- Trial name
- PCS2 (NCT01805778)
- Where
- 6 sites in United States, Canada
- Volunteers
- 1,128 people
- Sponsor
- The Hospital for Sick Children
Neoplasms
Low-dose CT-based Method for Detection of Subclinical Anthracycline-induced Cardiotoxicity
Prospective single arm study to evaluate a low-dose CT-based protocol for early detection of myocardial dysfunction in 50 cancer patients undergoing anthracycline-based chemotherapy.
- Trial name
- NCT03553654
- Testing
- low dose CT
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, San Diego
Cardiotoxicity, Breast Cancer
Dietary Restriction to Prevent Cardiotoxicity in Breast Cancer Patients
The goal of this clinical trial is to compare a dietary intervention with a regular diet in patients with early breast cancer undergoing anthracycline based chemotherapy.
- Trial name
- PROTECT-COR (NCT06622954)
- Testing
- Protein- and Calorie restriction
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Erasmus Medical Center
Anthracycline-induced Cardiac Toxicity, Breast Cancer
Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients
This study, called "ROSUBREAST", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based…
- Conditions
- Anthracycline-induced Cardiac Toxicity, Breast Cancer, Anthracycline Related Cardiotoxicity in Breast Cancer, Anthracycline-induced Cardiotoxicity
- Trial name
- ROSUBREAST (NCT07254221)
- Testing
- Rosuvastatin 20 mg/day
- Where
- 7 sites in Iran
- Volunteers
- 400 people
- Sponsor
- Shiraz University of Medical Sciences